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 Cardiovascular Research
and the Laboratory Mouse
A Jackson Laboratory Resource Manual
This resource manual highlights the importance of cardiovascular 
research and the extensive resources available for researchers at  
The Jackson Laboratory.
It briefly describes the following:
	 •	Over	30	JAX®	Mice	cardiovascular	research	models
	 •	 Summaries	of	recent	mouse-based	cardiovascular	research
	 •	Comparisons	of	cardiovascular	phenotypes	among	the 
	 	 Mouse	Phenome	Project	strains
	 •	Resources	available	through	our	Center	for	New	Models	of		 	
	 	 Heart,	Lung,	Blood,	and	Sleep	Disorders
	 •	Courses,	online	resources	and	JAX®	Services	suitable	for 
   cardiovascular research
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According	to	the	Centers	for	Disease	Control	(CDC:	 
www.cdc.gov/heartdisease/facts),	heart	disease	and	stroke	
are the first and third leading causes of death for both men 
and	women	in	the	United	States,	accounting	for	nearly	40%	
of	all	deaths	annually.	More	than	70	million	Americans	have	
some	kind	of	cardiovascular	disease.	Coronary	heart	disease	
is a leading cause of premature, permanent disability in the 
U.S.	workforce.	In	2006,	the	projected	cost	of	heart	disease	in	
the	U.S.	was	256	billion	dollars.
Two	of	the	major	independent	risk	factors	for	
cardiovascular diseases are high blood pressure and high 
blood	cholesterol.	Other	important	risk	factors	include	
diabetes, tobacco use, physical inactivity, poor nutrition, and 
obesity.	About	30%	of	U.S.	adults	have	high	blood	pressure,	
and	25%	have	high	cholesterol	levels.	A	12-	to	13-point	
reduction in blood pressure could reduce heart attacks by 
21%,	strokes	by	37%,	and	all	deaths	from	cardiovascular	
disease	by	25%.	A	10%	decrease	in	total	blood	cholesterol	
levels could reduce the incidence of coronary heart disease 
by	as	much	as	30%	(CDC:	www.cdc.gov/heartdisease/facts).
Although	a	great	deal	of	cardiovascular	research	 
has	already	been	conducted,	much	more	is	needed.	Our	
resources,	especially	our	JAX®	Mice	models	and	 
JAX®	Services,	will	undoubtedly	play	an	important	role	in	
that	research.	This	Resource	Manual	briefly	describes	the	
role of the laboratory mouse in cardiovascular research, 
selected	JAX®	Mice	models,	JAX®	Services,	online	resources	
applicable to cardiovascular research, and ongoing 
cardiovascular research conducted by our scientists.
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Atherosclerosis
Atherosclerosis,	also	called	coronary	heart	disease	(CHD),	
is essentially a chronic inflammatory reaction to modified 
lipoproteins, primarily oxidized low density lipoprotein 
(LDL).	It	is	one	of	the	most	devastating	of	human	diseases	
and a leading cause of death in industrialized countries 
(Kreger	et	al.	1994;	Beckman	et	al.	2002).	Older	women	
and	women	who	begin	hormone	therapy	over	10	years	
after menopause are at increased risk of developing 
atherosclerosis	(Rossouw	et	al.	2007).	Atherosclerosis	is	
particularly hard to fight because it is influenced by so many 
genetic	and	environmental	factors,	especially	diet	(Gylling	
and	Miettinen	2001;	Cohn	2002).
The laboratory mouse has played a crucial role in 
atherosclerosis research and will likely continue to do so 
(Paigen	1995;	Rader	and	Pure	2000;	Glass	and	Witztum	
2001;	Daugherty	2002;	Fazio	and	Linton	2002;	Allayee	 
et	al.	2004;	Wang	et	al.	2005a).	At	least	21	atherosclerosis	
quantitative	trait	loci	(QTLs)	have	been	identified	in	the	
mouse	(Wang	et	al.	2005a):	seven	in	high-fat	diet	models	
only,	nine	in	sensitized	models	(apolipoprotein	E-	or	low	
density	lipoprotein	receptor-deficient	mice)	only,	and	five	 
in both models. 
More	than	half	of	the	mouse	and	human	atherosclerosis	
QTLs	are	likely	concordant,	having	the	same	underlying	
genes	(Stoll	et	al.	2000;	Sugiyama	et	al.	2001;	Wang	et	al.	
2005a).	More	mouse	QTLs	concordant	with	human	QTLs	
could	possibly	be	found	1)	if	additional	crosses	using	
previously	unused	parental	strains	were	performed	(11	of	
the	13	crosses	performed	so	far	used	B6	mice	as	one	of	the	
parents),	2)	if,	in	addition	to	lesion	size,	characterization	
of the atherosclerosis phenotype in the mouse would 
incorporate	plaque	stability	(as	is	done	in	humans),	3)	
through	mutagenesis	screens,	and	4)	by	using	new	genomic	
and	bioinformatics	tools	(Wang	et	al.	2005a).	Performing	
additional	crosses	(with	atherosclerosis	susceptible	strains	
such	as	SM/J	and	SWR/J)	would	not	only	reveal	new	
atherosclerosis	QTLs	but	would	verify	previous	QTLs,	
providing	the	information	necessary	to	identify	QTL	genes	
(Wang	and	Paigen	2005;	Wang	 
et	al.	2004).
The genes underlying both human and mouse 
atherosclerosis	QTLs	are	largely	unknown.	Of	over	 
80	mouse	and	at	least	17	human	genes	known	to	influence	
atherosclerosis, only about a quarter fall into human 
atherosclerosis	QTLs	(Wang	et	al.	2005a).	Only	two	of	the	
genes	underlying	the	21	mouse	atherosclerosis	QTLs	have	
been identified, and half of the human atherosclerosis 
QTLs	have	no	obvious	candidate	genes	(Wang	et	al.	2005a).	
Because of concordance, discovering these genes in the 
mouse	first	will	be	much	more	cost-effective,	less	time	
consuming, and less fraught with ethical issues than would 
finding them in humans first, especially now that many new 
genetic, genomic, and bioinformatics tools for the mouse  
are available.
A map showing the location of mouse atherosclerosis QTLs 
(and their candidate genes) is available from The Jackson Laboratory’s 
Mouse Heart, Lung, Blood and Sleep Disorders Center (HLBS) website at this URL: 
pga.jax.org/qtl/index
The map is linked to resource tables that include chromosome locations, 
mouse crosses, statistical significances, and references for each QTL.
A map of human atherosclerosis QTLs (at least 27 have been reported) 
is available from the same website.
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Given	the	compelling	evidence	that	HDL	protects	against	
atherosclerosis	(Brewer	2004;	Gotto	and	Brinton	2004),	
human	atherosclerosis-regulating	genes	might	also	be	
identified	by	finding	the	genes	underlying	mouse	HDL	QTLs	
and	determining	if	their	orthologs	regulate	HDL	levels	and	
atherosclerosis	susceptibility	in	humans.	Many	QTLs	have	
been	found	that	regulate	plasma	levels	of	HDL	cholesterol	
(37	in	mice,	30	in	humans),	low	density	lipoprotein	(LDL)	
cholesterol	(25	in	mice,	20	in	humans)	and	triglycerides	
(19	in	mice,	30	in	humans).	Ninety-three	percent,	100%,	
and	80%	of	the	human	QTLs	for	HDL	cholesterol,	LDL	
cholesterol, and triglycerides respectively have concordant 
mouse	QTLs,	suggesting	they	have	the	same	underlying	
genes	(Wang	and	Paigen	2005a;	Wang	and	Paigen	2005b).	
Lipid Homeostasis
Identifying these genes should be facilitated considerably 
by	analyzing	haplotypes	(DiPetrillo	et	al.	2005;	Wang	et	al.	
2004),	data	combined	from	multiple	crosses	(Wittenburg	et	
al.	2006;	DiPetrillo	et	al.	2005),	and	by	using	the	mouse-to-
human-to-mouse	paradigm	(Wang	and	Paigen	2005b).	
Maps of HDL, LDL, and triglyceride QTLs (and candidate 
genes) found in the mouse can be accessed from the HLBS 
website: pga.jax.org/qtl/index. Each map is linked to 
resource tables that include chromosome locations, mouse 
crosses, statistical significances, and references for each QTL. 
Maps of human QTLs for the same phenotypes are accessible 
from the same site.
Hypertension
Human hypertension greatly increases the risk of 
coronary heart disease, congestive heart failure, stroke, 
and	kidney	disease.	Additionally,	it	is	often	associated	with	
and	complicated	by	obesity,	dyslipidemia,	and	non-insulin	
dependent	diabetes	mellitus	(NIDDM)	(Bonora	et	al.	1998).	
More	than	50	million	Americans	suffer	from	hypertension,	
and 12.7 million of them alleviate its symptoms by taking 
medicinal	drugs	(Smith	2000).	The	alleles	associated	with	
essential hypertension in humans have been difficult to 
find because the genetic backgrounds and environmental 
influences in human populations are almost impossible to 
control. These have been much easier to control in inbred 
rodent populations.
Preeclampsia
Preeclampsia	is	a	disorder	that	occurs	only	during	
pregnancy and the postpartum period and affects both the 
mother	and	the	unborn	baby.	Occuring	in	at	least	five	to	
eight percent of all pregnancies, preeclampsia is a rapidly 
progressive condition characterized by high blood pressure 
and	protein	in	the	urine.	Although	symptoms	may	include	
Blood Pressure
swelling, sudden weight gain, headaches, and changes in 
vision, some women with rapidly advancing disease report 
few symptoms. 
Typically,	preeclampsia	occurs	after	20	weeks	gestation,	
but it can occur earlier. To diagnose and manage it, 
proper	prenatal	care	is	essential.	Preeclampsia	and	other	
hypertensive disorders of pregnancy are a leading global 
cause of maternal and infant illness and death, accounting 
for	at	least	76,000	deaths	yearly	(The	Preeclampsia	
Foundation,	www.preeclampsia.org).
The Emergence of the Mouse as a Blood 
Pressure Model
Until recently, the rodent model most widely used to 
study hypertension was the laboratory rat. With the advent 
of genetic engineering and the development of equipment 
capable of measuring blood pressure in small organisms, 
the mouse has assumed an increasingly important role as 
a	model	in	blood	pressure	studies	(Sugiyama	et	al.	2001a,	
2001b,	2002;	DiPetrillo	et	al.	2004;	Tsukahara	et	al.	2004).
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Professor Beverly Paigen, Ph.D. 
www.jax.org/research/faculty/beverly_paigen
Professor	Paigen	and	her	laboratory	research	the	genetic	
and environmental factors associated with atherosclerosis, 
hypertension,	high	density	lipoprotein	(HDL)-cholesterol	 
levels, and cholesterol gallstone formation. Her staff and 
colleagues	Professor	Gary	Churchill	and	Research	Associate	
Renhua	Li	are	pioneers	in	developing	the	technology	and	
statistical	tools	for	mapping	quantitative	trait	loci	(QTLs)	
and identifying underlying alleles associated with these 
diseases.	In	the	past	10	years,	they	have	carried	out	over	 
25	QTL	mouse	crosses	and	have	discovered	over	250	
disease-associated	QTLs.	Once	they	identify	the	disease-
causing alleles in the mouse, they and collaborators seek 
to identify the orthologous alleles in humans. By using 
a variety of comparative genetic approaches, they have 
already identified one allele associated with susceptibility 
to atherosclerosis and two associated with susceptibility to 
hypertension in humans.
Professor	Paigen	and	her	colleagues	have	also	contributed	
a considerable amount of cardiovascular related data to the 
Mouse	Phenome	Database.
Cardiovascular Research at The Jackson Laboratory
Professor	Beverly	Paigen	(center	row,	second	from	right)	along	with	her	research	staff.
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Our Facilities
The Jackson Laboratory comprises two facilities: an East 
Coast	campus	in	Bar	Harbor,	Maine	and	a	West	Coast	
campus	in	Sacramento,	California.	On	both	campuses	
cardiovascular research, services and educational activities 
take place. 
The Jackson Laboratory repository on the Bar Harbor 
campus	is	home	to	more	than	4,000	strains	of	JAX®	Mice	
and	growing	daily.	More	than	1,200	of	these	strains	are	
maintained as live colonies and are available for distribution 
to	biomedical	researchers	worldwide.	All	of	these	strains,	
including the live colonies, are cryopreserved to ensure they 
continue to be available to the scientific community for 
many years to come. This growing resource is the result of 
the donation of hundreds of unique mouse models every 
year by researchers around the world in an effort to preserve 
today what may lead to the prevention and cure many 
human diseases.
Bar Harbor, ME facility 
•	 Primary	production	and	distribution	site	for	more	than	
4,000	genetically	defined	mouse	strains
•	 Research	Staff	of	more	than	200	Ph.D.s,	M.D.s,	and	
D.V.M.s	
•	 Center	for	the	Mouse	Tumor	Biology	Database	(MTB),	
Mouse	Genome	Informatics	Database,	and	the	Mouse	
Phenome	Database	(MPD)
•	 World-renowned	Courses	and	Conferences,	and	
training programs
•	 Model	preconditioning	and	surgical	services	
•	 Revolutionary	cryopreservation	and	recovery	services
•	 Genetic	research	services	(including	gene	mapping	and	
speed	congenics)
•	 Microinjection	services	for	new	model	development
•	 Comprehensive	and	integrated	mouse	breeding	and	
research services designed to provide efficient and  
cost-effective	solutions	for	mouse-based	research	
Sacramento, CA facility
•	 Site	of	JAX®	In Vivo Services
•	 Production	and	distribution	site	for	our	most	popular	
JAX®	Mice
•	 State-of-the-art	phenotyping	laboratory	for	
characterizing models, validating drug targets, and 
testing drug efficacy
•	 Highly	trained	scientific	staff,	with	experience	
conducting in vivo studies	in	over	100	mouse	models
•	 Comprehensive	and	integrated	mouse	breeding	and	
research	services	designed	to	provide	efficient	and	cost-
effective	solutions	for	mouse-based	research
With	nearly	80	years	experience	breeding	and	using	mouse	
models	of	disease,	the	quality	of	JAX®	Mice	&	Services	offered	
at	our	facilities	is	unmatched.	Our	commitment	drives	our	
mission: We discover the genetic basis for preventing, treating 
and curing human diseases, and we enable research and 
education for the global biomedical community.
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Why Choose JAX® Mice
There	are	many	reasons	why	you	should	choose	JAX®	Mice	
for your cardiovascular research:
•	 JAX®	Mice	are	the	universally	recognized	gold standard 
for	genetically	well-defined	laboratory	mice.	Their	
stable genotypes and phenotypes are the result of our  
three-component	Genetic	Quality	Control	Program.	
 This program includes:
1)	Adherence	to	best	practices	in	breeding	and	 
colony management 
2)	The	use	of	molecular	test	methods	to	confirm	
genetic identity and genotypes 
3)	Phenotype	monitoring
•	 JAX®	Mice	colonies	are	rigorously	monitored	for	
both	pathogenic	and	opportunistic	agents.	Our	
comprehensive	biosecurity	program	and	state-of-the-art	
facilities	ensure	the	health	quality	of	JAX®	Mice.
•	 JAX®	Mice	are	the	most	comprehensively	characterized	
laboratory mice as noted below: 
1)	The	C57BL/6J	strain	(000664)	is	the	only	fully	
sequenced	mouse	strain;	
2)	The	National	Institute	of	Environmental	Health	
Sciences	(NIEHS)	has	resequenced	15	JAX®	Mice	
strains	(SNP	information	available	in	the	Mouse	
Phenome	Database,	www.jax.org/phenome);
3)	JAX®	Mice	were	used	to	construct	the	most	detailed	
genetic map of any mammal except humans 
(Shifman	et	al.	2006);	
4)	40	genetically-diverse	and	widely-used	JAX®	Mice	
strains are being comprehensively characterized  
by	the	Mouse	Phenome	Project	 
(www.jax.org/phenome).
•	 The	JAX®	Mice	Database	(www.jax.org/jaxmice/query)	
and	the	Mouse	Genome	Database	(www.informatics.
jax.org)	are	renowned	for	their	wealth	of	genotypic	and	
phenotypic information.
•	 JAX®	Mice	are	the	most	widely	published	laboratory	
mice.	They	have	been	referenced	in	more	than	20,000	
peer-reviewed	publications.	Over	90%	of	the	published	
references	to	B6	substrains	cite	our	C57BL/6J	strain.
•	 Over	4,000	JAX®	Mice	strains	are	available,	including	
inbred, hybrid, genetically engineered, recombinant 
inbred, chromosome substitution, recombinant 
congenic, and congenic strains.
•	 JAX®	Mice	are	used	for	cardiovascular	research	in	
medical schools, universities, and research centers all 
over the world.
•	 Our	Technical	Information	Support	and	Customer	
Service	teams	leverage	the	expertise	of	our	research	staff	
and mouse breeding experts to offer comprehensive and 
integrated support to help you conduct your research 
with	JAX®	Mice.
•	 JAX®	Mice	users	have	ready	access	to	JAX®	Services,	a	
comprehensive and highly customizable set of mouse 
breeding	and	research	services	designed	for	the	mouse-
based biomedical research community  
(see	JAX®	Services	section	in	this	manual).
JAX® Mice Models
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Importance of Genetic Background 
You may occasionally see the following cautionary note in 
JAX®	Mice	strain	data	sheets:
This strain is on a genetic background different from that 
on which the allele was first characterized. It should be 
noted that the phenotype could vary from that originally 
described. We will modify the strain description if 
necessary as published results become available.
We include this note because the technology for producing 
genetically-engineered	mice	has	been	substantially	refined,	
resulting	in	an	ever-increasing	number,	variety,	and	
availability	of	mutant	mouse	models.	Similarly,	the	variety	
of genetic backgrounds and the mutations characterized and 
published on them are continually increasing. Generally, 
alleles	of	interest	(such	as	spontaneous	mutations,	targeted	
mutations,	transgenes,	and	congenic	regions)	are	maintained	
on	one	to	several	genetic	backgrounds.	One	background	
may be more vigorous, better characterized, more amenable 
to scientific experiments, reproduce better, display a more 
severe phenotype, or have some other advantages over 
other backgrounds. However, these alleles are sometimes 
transferred to backgrounds that are not well characterized. 
Inattention to a mutant’s genetic background can seriously 
confound research results. Each strain has unique 
background alleles that may interact with and modify 
the expression of a mutation, transgene, or other genetic 
alteration. The likelihood of such modifier genes having a 
confounding effect is especially high in an uncharacterized 
background or in a segregating or mixed background of 
unspecified	origin.	Even	in	a	well-characterized	strain,	
undiscovered modifier genes may alter results, sometimes 
making them unexplainable. Thus, before you decide which 
mouse strain is appropriate for your research, consider its 
genetic background.
JAX® Mice Models
The Mouse-to-Human-to-Mouse Paradigm
Professor	Beverly	Paigen	of	The	Jackson	Laboratory	and	other	investigators	have	
successfully	used	the	mouse-to-human-to-mouse	paradigm	to	identify	human	
disease alleles. The process is as follows:
•	 Identify	disease	QTLs	and	the	most	promising	candidate	genes	in	the	mouse.
•	 Determine	if	polymorphisms	in	the	human	orthologs	of	these	candidate	genes	
are associated with the same disease in humans.
•	 Return	to	the	mouse	to	obtain	experimental	proof	that	polymorphisms	of	the	
gene can cause the disease.
The paradigm has been used successfully to establish the following  
gene-disease	relationships:
•		TNFSF4	(encoding	OX40	ligand)	is	significantly	associated	with	myocardial	
infarction	and	coronary	artery	disease	in	humans	(Wang	et al.	2005b);
•	 CTLA4	(encoding	cytotoxic	T-lymphocyte-associated	protein	4)	is	
significantly associated with autoimmune disorders, including Graves disease, 
autoimmune	hypothyroidism,	and	type	1	diabetes	(Ueda	et	al.	2003);
•		POMC (encoding	pro-opiomelanocortin-alpha	[MIM	176830])	is	significantly	
associated	with	obesity	(Krude	et	al.	1998;	Hixson	et	al.	1999);	
• EN2	(encoding	engrailed	2	[MIM	131310])	is	significantly	associated	with	
autism-spectrum	disorder	(Gharani	et	al.	2004).
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In	the	following	pages,	we	describe	over	30	of	the	most	
commonly	used	and	promising	JAX®	Mice	models	suitable	
for cardiovascular research. The descriptions are abridged 
from	the	JAX®	Mice	Database	and	scientific	journals.	For	
more detailed information and/or comprehensive lists, 
consult the following:
•	 JAX® Mice Database (www.jax.org/jaxmice):  
The JAX® Mice	Database	is	the	most	comprehensive	
source	of	JAX®	Mice	strain	information.	Many	of	
the strains are described according to mammalian 
phenotype	terms.	Strains	for	cardiovascular	research	
can be searched by research area.
	•	  The Mouse Phenome Database  
(MPD, www.jax.org/phenome): The	MPD	is	the	
database	for	the	Mouse	Phenome	Project,	a	coordinated	
international effort to establish a collection of baseline 
phenotypic data for a set of commonly used and 
genetically diverse inbred mouse strains.
•	 The Center for New Mouse Models of Heart, Lung, 
Blood, and Sleep Disorders (www.nhlbi.nih.gov/
resources/pga):	The	goal	of	the	JAX®	HLBS	Center	is	to	
provide the biomedical research community with new 
information, tools, and resources for understanding 
the genetic bases of atherosclerosis, hypertension, lung 
function, blood formation, thrombosis, obesity, and 
sleep function.
•	 The Cardiovascular Models Research Page  
(www.jax.org/jaxmice/research/cardiovascular): 
This	downloadable	pdf	lists	over	125	JAX®	Mice	
strains	suitable	for	cardiovascular	research.	Strains	are	
categorized	by	research	area	(such	as	atherosclerosis,	
hypertension,	hypercholesteremia,	etc.)	and	gene	symbol.
•	 References: References	are	provided	with	each	strain	
description	in	this	manual.	Additional	ones	are	available	
from	the	strain	data	sheets	in	the	JAX®	Mice	Database.
 JAX® Mice Models
JAX® Mice Models
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The Mouse Phenome Project Strains
Although	many	JAX®	Mice	strains	have	been	used	to	
research atherosclerosis, they have been insufficient for 
unraveling	all	the	biochemical	pathways	involved	(Wang	 
et	al.	2005a).	Until	recently,	choosing	other	strains	was	
difficult because atherosclerosis susceptibility and its 
subphenotypes	(such	as	cholesterol	and	triglyceride	levels)	
in most mouse strains were largely uncharacterized.  
Professor	Paigen	of	The	Jackson	Laboratory,	her	colleagues,	
and	other	participants	in	the	Mouse	Phenome	Project	have	
helped remedy that situation by extensively characterizing 
these	phenotypes	for	the	Mouse	Phenome	Project	strains	
and	submitting	their	data	to	the	Mouse	Phenome	Database	
(www.jax.org/phenome).	
Atherosclerosis Susceptibility 
and Infectious Agents
One	of	the	environmental	factors	receiving	considerable	
attention as a risk factor for the development of chronic 
inflammatory	diseases,	including	Crohn’s	disease,	psoriasis,	
type 2 diabetes, and atherosclerosis, is the aggravating 
or	precipitating	influence	of	infectious	agents	(Karin	et	
al. 2006	Pellicano	et	al.	1999).	In	mice,	infections	with	
cytomegalovirus,	Chlamydia,	or	Porphyromonas gingivalis 
have been found to increase the severity of atherosclerosis 
(Vliegen	et	al.	2005,	2004,	2002;	Chi	et	al.	2004;	Burnett	
et	al.	2001;	Hsich	et	al.	2001).	Similarly,	in	her	nearly	20	
years of experience researching the genetic determinants 
of	atherosclerosis	in	mouse	models,	Dr.	Paigen	observed	
that the degree to which mice develop atherosclerosis 
seemed to depend on the presence of infectious agents in 
the	environment	(pers.	comm.).	To	test	her	hypothesis,	she	
and	her	colleagues	examined	the	diet-induced	susceptibility	
to	atherosclerosis	in	the	Mouse	Phenome	Project	strains	in	
barrier	and	non-barrier	mouse	rooms	(Table	1)	(Paigen	et	al.	
2000a;	2000b).	The	barrier	rooms	were	regularly	monitored	
for	and	maintained	free	of	15	viruses	(mouse	hepatitis	
virus, two mouse parvoviruses, reovirus, Theiler’s mouse 
encephalomyelitis virus, ectromelia virus, mouse rotavirus, 
thymic	virus,	pneumonia	virus	of	mice,	Sendai	virus,	murine	
cytomegalovirus,	lactic	dehydrogenase-elevating	virus,	K	
virus,	mouse	adenovirus,	and	polyoma	virus),	17	bacterial	
species	(including	Helicobacter spp. and Pneumocystis 
pneumotropica),	two	Mycoplasma species, external and 
internal parasites, and Encephalitozoon cuniculi.	Personnel	
entering these rooms were required to wear caps, facemasks, 
disposable	gowns,	shoe	covers,	and	gloves.	At	the	time,	the	
only	known	infectious	agents	in	the	non-barrier	facilities	
were Helicobacter sp, Pneumocystis, and Pasturella.
All	mice	were	fed	the	same	diet:	however,	whereas	mice	in	
the barrier facilities were fed an atherogenic diet for  
17	weeks,	those	in	non-barrier	facilities	were	fed	the	diet	for	
8 weeks.
Table 1 and the more detailed information in the  
Mouse	Phenome	Database	should	help	researchers	find	
more	atherosclerosis	QTLs,	identify	the	underlying	genes,	
and determine how infectious agents influence susceptibility 
to atherosclerosis.
Atherosclerosis
A map showing the location of atherosclerosis QTLs  
identified in the mouse (and their candidate genes)  
is available at pga.jax.org/qtl/index.
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Table 1.	Susceptibility	to	diet-induced	atherosclerosis	in	Mouse	Phenome	Project	strains	housed	in	non-barrier	and	barrier	
rooms.
A/J,	BALB/cJ,	
BPH/2J,	BPL/1J,	
BUB/BnJ,  
CAST/EiJ,	CBA/J,	
CE/J,	CZECHII/EiJ,	 
FVB/NJ,	KK/HlJ,	 
MOLF/EiJ,	 
NOD/ShiLtJ,	 
NON/ShiLtJ,	 
NZB/BlNJ,	 
NZW/LacJ,	 
PERA/EiJ,	RIIIS/J,	
SPRET/EiJ,	WSB/EiJ
129S1/SvlmJ,	A/J,	
AKR/J,	BALB/cJ,	
BPH/2J,	BPL/1J,	 
C57L/J,	CAST/EiJ,	
CBA/J,	CE/J,	 
CZECHII/EiJ,	
DBA/2J,	 
FVB/NJ,	KK/HlJ,	
LP/J,	MOLF/EiJ,	
PERA/EiJ,	RF/J,	
SPRET/EiJ,	 
WSB/EiJ
M
al
es
Fe
m
al
es
129S1/SvlmJ,	A/J,	
AKR/J,	C3H/HeJ,	
C57BL/10J,	C57L/J,	
CBA/J,	CZECHI/EiJ,	
DBA/2J,	FVB/NJ,	 
JF1/Ms,	KK/HlJ,	 
MSM/Ms,	 
NZW/LacJ,	 
PERA/EiJ,	PL/J,	 
PWK/PhJ,	 
SEA/GnJ,	SL/J,	 
SPRET/EiJ,
129S1/SvlmJ,	 
BTBR	T+ tf/J,  
BUB/BnJ,	C57BL/10J,	 
C57BR/cdJ,	C57L/J,	 
CAST/EiJ,	CBA/J,	
CZECHI/EiJ,	DBA/1J,	
DBA/2J,	JF1/Ms,	 
MA/MyJ,	MSM/Ms,	
NOD/ShiLtJ,	 
NZW/LacJ,	PERA/
EiJ,	PL/J,	PWK/PhJ,	
SL/J,	WSB/EiJ
129S1/SvlmJ,	AKR/J,	
BPN/3J,	 
BTBR	T+ tf/J,  
C3H/HeJ,	
C57BL/10J,	DBA/1J,	
DBA/2J,	I/LnJ,	LP/J,	
P/J,	PL/J,	RBF/DnJ,	
RF/J,	SJL/J,	SWR/J,	 
YBR/EiJ
BTBR	T+ tf/J,  
C3H/HeJ,C57BL/10J,	
C57BR/cdJ,	DBA/1J,	
I/LnJ,	NOD/ShiLtJ,	
NON/ShiLtJ,	 
NZB/BlNJ,	 
NZW/LacJ,	P/J,	 
RBF/DnJ,	RIIIS/J,	
SEA/GnJ,	SWR/J
BALB/cByJ,	 
BUB/BnJ,	C57BL/6J,	
CAST/EiJ,	DBA/1J,	
LP/J,	NOD/ShiLtJ,	
NZB/BINJ,	RF/J,	
RIIIS/J,	WSB/EiJ
BALB/cByJ,	BALB/cJ,	
C3H/HeJ,	C57BL/6J,	
FVB/NJ,	I/LnJ,	LP/J,	
NZB/BINJ,	RIIIS/J,	
SM/J,	SPRET/EiJ,	
SWR/J
C57BL/6J,	
C57BLKS/J,	 
C57BR/cdJ,	C57L/J,	
C58/J,	SEA/GnJ,	
SM/J
C57BL/6J,	 
C57BLKS/J,	C58/J,	
SJL/J,	SM/J
BALB/cJ,	 
BTBR	T+ tf/J, 
C57BLKS/J,	 
C57BR/cdJ,	C58/J,	 
I/LnJ,	MA/MyJ,	
MOLF/EiJ,	 
NON/ShiLtJ,	 
SEA/GnJ,	SM/J,	
SWR/J
A/J,	C57BLKS/J,	 
C58/J,	MOLF/EiJ,	
NON/ShiLtJ
Non-barrier Non-barrier Non-barrierBarrier Barrier Barrier
Intermediately Susceptible
mean lesion size: 1 to 499 µm2
Resistant
mean lesion size: 0 µm2
Very Susceptible
mean lesion size: > 500 µm2
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mice	do	not	become	diabetic	(Nishina	et	al.	1994;	
Noben-Trauth	et	al.	1996).	When	maintained	
in	non-barrier	facilities,	despite	having	elevated	
plasma	total	cholesterol,	triglyceride,	and	HDL	
cholesterol levels, B6 mice homozygous for the 
Tubtub	mutation	are	resistant	to	diet-induced	
atherosclerosis	(Table	2).	
increased.	When	maintained	in	non-barrier	
facilities, this strain is intermediately susceptible 
to	diet-induced	atherosclerosis	(Table	2).
Homozygotes for the tubby spontaneous 
mutation	develop	late-onset	obesity,	recognizable	
at three to four months in males and at four to 
six months in females. The increased weight is 
composed of excess adipose tissue. Blood glucose 
is	normal.	Although	plasma	insulin	levels	rise	
before	obvious	signs	of	obesity	and	may	be	20	
times	above	normal	in	six-month	olds,	tubby	
Homozygotes for the Leprdb spontaneous 
mutation	with	a	BKS	background	become	obese,	
hyperinsulemic, and hyperglycemic. They are 
polyphagic,	polydipsic,	and	polyuric.	Most	die	
by	10	months	of	age.	They	develop	peripheral	
neuropathy and myocardial disease. Wound 
healing is delayed, and metabolic efficiency is 
B6(Cg)-Tubtub/J   000562
BKS.Cg-m +/+ Leprdb/J    000642
Atherogenic Diet and 
Cholesterol Homeostasis
Professor	Paigen	characterized	the	effects	of	an	
atherogenic	diet	on	cholesterol	homeostasis	in	the	Mouse	
Phenome	Project	strains	in	the	same	non-barrier	and	
barrier	facilities	(Paigen	et	al.	2000a,	2002).	In	non-barrier	
facilities,	mice	were	fed	the	atherogenic	diet	for	eight	weeks;	
in barrier facilities, they were fed the diet for 17 weeks. 
All	raw	data	and	protocols	are	published	in	the	Mouse	
Phenome	Database,	www.jax.org/phenome.
Cholesterol	subphenotypes	characterized	in	non-barrier	
facilities	included	total	plasma	cholesterol,	HDL	plasma	
cholesterol,	non-HDL	plasma	cholesterol,	%	plasma	HDL	
cholesterol, free hepatic cholesterol, esterified hepatic 
cholesterol, and total hepatic cholesterol. 
Cholesterol	subphenotypes	measured	in	barrier	 
facilities	included	HDL	cholesterol,	non-HDL	cholesterol,	
total	cholesterol,	fold	change	in	HDL	cholesterol,	and	non-
HDL	cholesterol.
Atherogenic Diet and Triglyceride Levels
Professor	Paigen	characterized	the	triglyceride	levels	of	
the	Mouse	Phenome	Project	strains	maintained	in	barrier	
facilities before and after they were fed an atherogenic  
diet	for	17	weeks	(Paigen	et	al.	2002).	All	raw	data	and	
protocols	are	published	in	the	Mouse	Phenome	Database,	
www.jax.org/phenome.
Obesity Mutants 
Several	obesity	mutants	may	be	useful	for	researching	
atherosclerosis.	Paigen	et	al.	(2000b)	determined	the	diet-
induced susceptibility to atherosclerosis of the following 
four	obesity	mutants	housed	in	non-barrier	rooms:
JAX® Mice Models  Atherosclerosis
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non-barrier	facilities,	they	are	very	susceptible	to	
diet-induced	atherosclerosis	(Table	2).	
permanently hyperinsulinemic by four weeks 
of	age	(JAX®	Notes	2002;	Naggert	et	al.	1995;	
Nillni	et	al.	2002;	Weide	and	Lacy	1991).	When	
maintained	in	non-barrier	facilities,	they	are	very	
susceptible	to	diet-induced	atherosclerosis	 
(Table	2).
B6.Cg-Ay/J heterozygotes become obese but 
only	mildly	diabetic	(Reddi	and	Camerini-Davalos	
RA	1988;	Taylor	et	al.	1999).	When	maintained	in	
Male	BKSChpLt.HRS-Cpefat/J homozygotes 
become diabetic, grossly obese, and severely 
hyperglycemic	(their	glucose	levels	plateau	
at	about	400-600	mg/dl).	Both	sexes	become	
obese by six to eight weeks of age and are 
distinguishable	from	wild-type	littermates	by	
eight to 12 weeks of age. They are severely and 
B6.Cg-Ay/J   000021
BKSChpLt.HRS-Cpefat/J  002391
Table 2.	Effects	of	atherogenic	diet	on	susceptibility	to	atherosclerosis	in	both	sexes	of	four	obesity	mutants	housed	in	non-
barrier	facilities	(Paigen	et	al.	2000b).
The Jackson Laboratory Mouse Heart, 
Lung, Blood, and Sleep Disorders 
Center
The	Heart,	Lung,	Blood,	and	Sleep	Disorders	Center	
(HLBS)	is	producing	many	chemically-induced	mouse	
models	suitable	for	cardiovascular	research.	Characterized	
and	proven-heritable	mutants	are	available	to	academic	
Resistant
mean lesion size: 0 µm2
B6(Cg)-Tubtub/J 
(000562)
BKS.Cg-m +/+ Leprdb/J
 (000642)
B6.Cg-Ay/J (000021)
BKSChpLt.HRS-Cpefat/J (002391)
Intermediately Susceptible
mean lesion size: 1-499 µm2
Very Susceptible
mean lesion size > 500 µm2
researchers	for	the	cost	of	shipping	only	(for-profit	
organizations	are	charged	an	additional	fee).	Instructions	for	
ordering	are	on	the	Center’s	website,	pga.jax.org.
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The	Center	maintains	approximately	200	lines	at	one	
of the following three stages of development: not yet proven 
heritable, heritable and available to ship, and in the process of 
being	mapped.	As	of	May	2008,	37	heritable	and	ready-to-ship	
mutants and nine phenotypic deviants have cardiovascular 
defects: 14 of the heritable mutants and one of the phenotypic 
deviants	have	cholesterol	disorders	(Table	3).
Table 3.	Number	of	heritable	(ready-to-ship)	mutants	and	phenotypic	deviants	suitable	for	cardiovascular	research	identified	
by	the	HLBS	Center	(as	of	May	2008).
*QT,	PR,	and	QTC	refer	to	heart	beat	intervals	displayed	on	an	electrocardiogram.
Cardiovascular Phenotypes Number ofHeritable Mutants
Number of
Phenotypic Deviants
Bradycardia (some with prolonged QT* 
and PR* intervals)
Prolonged PR*, QT*, QTC* intervals
Diet-induced high HDL and 
hypercholesterolemia
Dilated cardiomyopathy
Trachycardia
High heart rate variability
Diet-induced hypercholesterolemia
Diet-induced hypercholesterolemia and 
low HDL
Hypocholesterolemia and low HDL
High triglyceride levels
Low HDL
High HDL
Hypertension
High HDL and triglyceride levels
2
2
2
2
1
1
2
2
1
1
1
2
2
6
1
1
15
2
Ch
ol
es
te
ro
l D
iso
rd
er
s
Ca
rd
ia
c D
ys
fu
nc
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n
Loci	associated	with	high	cholesterol	and	low	HDL	 
have	been	mapped.	For	more	detailed	information	about	
these	mapped	mutants,	consult	the	Mapped	Mutant	Matrix	 
at	pga.jax.org/resources/mappedmutants.
Register to receive alerts of new JAX® HLBS mutants at  
pga.jax.org/resources/alert_list.
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Selected JAX® Mice Atherosclerosis Models
Homozygotes for these targeted mutations  
of	the	ATP-binding	cassette,	sub-family	G	
(WHITE),	member	5	(Abcg5)	and	ATP-binding	
cassette,	sub-family	G	(WHITE),	member	 
8	(Abcg8)	genes	are	viable	and	look	and	behave	
normally. Their plasma sitosterol levels are  
B6;129S6-Abcg5/Abcg8 tm1Hobb/J  004670
30	times	higher	than	normal.	Their	biliary,	
plasma, and liver cholesterol levels are low. Their 
plasma and liver cholesterol levels increase 
rapidly	(2.4	and	18	fold,	respectively)	following	
cholesterol	feeding	(Yu	et	al.	2002).	
Homozygotes	for	this	apolipoprotein	A-I	
(Apoa1)	targeted	mutation	appear	to	develop	
normally	despite	having	no	APOA1	protein.	
Additionally,	after	being	fasted	overnight,	they	
have severely reduced levels of plasma cholesterol 
and	HDL-cholesterol,	and	they	are	deficient	in	
alpha-migrating	HDL	particles	(Williamson	
B6.129P2-Apoa1tm1Unc/J  002055
et	al.	1992).	Although	ApoaI deficiency delays 
cholesterol absorption, cholesterol is eventually 
absorbed because of the compensatory Apob 
pathway.	Nonetheless,	long-term	studies	involving	
multiple feedings indicate significant reduction in 
cholesterol	absorption	after	four	days	(Iqbal	and	
Hussain	2005).
Considerable	evidence	indicates	that	a	high	
concentration	of	APOA1	in	the	artery	wall	
enhances cellular cholesterol efflux and protects 
against	atherosclerosis.	Mice	homozygous	for	the	
human	apolipoprotein	A-I	(APOA1)	transgene	
(under	control	of	its	natural	promoter)	are	viable,	
fertile,	and	normal-sized.	They	have	twice	as	
much total plasma cholesterol but over four times 
less	mouse	APOAI	than	normal.	They	have	a	
reduced	susceptibility	to	diet-induced	fatty	streak	
lesions	(Rubin	et	al.	1991).
Mice	with	this	targeted	mutation	of	the	
apolipoprotein	B	(Apob)	gene	produce	a	truncated	
form	of	the	apolipoprotein	B	protein	(APOB70)	
and	no	APOB100,	resulting	in	a	condition	similar	
to human familial hypobetalipoproteinemia. 
These	mice	express	normal	amounts	of	APOB48.	
Homozygotes have greatly reduced levels of 
C57BL/6-Tg(APOA1)1Rub/J  001927
B6.129P2-Apob tm1Unc/J  002053
Major	et	al.	(2001)	found	that	atherosclerotic	
lesions in mice Apoe-deficient	and	also	
transgenic	for	human	APOA1	under	the	control	
of	a	macrophage-specific	scavenger	receptor-A	
promoter	are	96%	smaller	than	those	in	mice	
that are only Apoe-deficient.	Atherosclerosis	
resistance in these mice has been attributed to 
the production of human APOA1 protein and 
the consequently increased cholesterol efflux by 
macrophages in the artery wall.
plasma	APOB,	beta-lipoproteins,	total	cholesterol,	
plasma triglycerides, fasting chylomicronemia, 
and	HDL	cholesterol.	Homozygotes	also	have	a	
high incidence of exencephaly and hydrocephaly 
(Homanics	et	al.	1993).	
JAX® Mice Models  Atherosclerosis
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Apolipoprotein	(apoE)	is	a	glycoprotein	
synthesized in the liver, brain, and other tissues 
in both humans and mice. It is a structural 
component of all lipoprotein particles other than 
LDL.	One	of	its	most	important	functions	is	to	
serve as a high affinity ligand for the apoB and 
apoE	(LDL)	receptor	and	for	the	chylomicron	
remnant receptor, thereby allowing the uptake of 
apoE-containing	particles	by	the	liver	(Jawien	et	
al.	2004).
Because they are hypercholesterolemic and 
spontaneously develop arterial lesions, Apoe-
deficient mice are one of the most relevant models 
for atherosclerosis research. They develop lesions 
more	quickly	if	fed	a	Western	diet	(containing	
21%	fat	and	0.15%	cholesterol),	and	even	more	
quickly	if	fed	a	high-cholesterol	diet	(containing	
15%	fat,	1.25%	cholesterol,	and	0.5%	cholic	acid)	
(Jawien	et	al.	2004).
B6.129P2-Apoetm1Unc/J  002052
The progression of atherosclerosis in this model 
is very similar to that in humans. By three months 
of age, homozygous mutants develop fatty streaks 
in the proximal aorta. With age, they develop 
more lesions with relatively less lipid but more 
elongated	cells,	typical	of	the	advanced	stage	pre-
atherosclerotic lesions.
Because atherosclerotic plaques in coronary 
arteries are particularly critical, future genome 
scans in mice should perhaps include coronary 
atherosclerosis	as	a	phenotype	(Wang	et	al.	2005).	
Advanced	atherosclerotic	lesions	do	occur	in	the	
coronary arteries of Apoe-	and/or	Ldlr-deficient	
mice and in Scarb1-deficient	mice	fed	either	chow	
(Braun	et	al.	2002)	or	a	high-cholesterol	diet	
(Caligiuri	et	al.	1999;	Calara	et	al.	2001).
 
Mice	homozygous	for	both	Apoe and the 
Ldlr targeted, null mutations develop severe 
hyperlipidemia and atherosclerosis. Even  
when fed a regular chow diet, they usually  
develop a more severe atherosclerosis than do 
B6.129-Apoetm1Unc Ldlrtm1Her/J  002246
Apoe-deficient	mice.	These	mice	do	not	have	to	 
be fed an atherogenic diet when used to test the  
anti-atherosclerotic	effects	of	compounds	(Jawien	
et	al.	2004).	
These	low	density	lipoprotein	receptor-(Ldlr-)
deficient mice have high serum cholesterol levels 
(200-400	mg/dl)	and	very	high	levels	 
(>	2,000	mg/dl)	when	fed	a	high	fat	diet	(levels	in	
normal	mice	are	80-100	mg/dl).	Although	they	
B6.129S7-Ldlrtm1Her/J  002207
develop atherosclerotic lesions spontaneously 
when fed a chow diet, the lesions are small and 
develop slowly. The lesions develop much faster 
in mice fed either a high cholesterol or a Western 
diet	(Jawien	et	al.	2004).	
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The class B, type I scavenger receptor Scarb1 
is	a	cell	surface	HDL	receptor	that	can	recognize	
the	apolipoproteins	on	the	surface	of	the	HDL	
particle. It plays a key role in determining the 
levels	of	plasma	lipoprotein	cholesterol	(primarily	
HDL)	and	the	accumulation	of	cholesterol	stores	
in the adrenal gland. The plasma cholesterol 
(primarily	HDL)	concentrations	in	Scarb1tm1Kri 
heterozygotes	and	homozygotes	are	31%	and	
B6;129S2-Scarb1tm1Kri/J  003379
125%	higher,	respectively,	than	they	are	in	
wild-type	controls.	Additionally,	cholesterol	
levels in the adrenal tissues of heterozygotes and 
homozygotes	are	42%	and	72%	lower,	respectively,	
than	they	are	in	wild-type	controls.	The	plasma	
concentrations	of	APOAI,	the	major	protein	in	
HDL,	in	these	mutants	is	comparable	to	that	of	
wild-type	controls	(Braun	et	al.	2002).
Homozygotes for the Apobtm1Unc targeted 
mutation produce a truncated form of the 
apolipoprotein	B	protein	APOB70	and	no	
APOB100,	resulting	in	a	condition	similar	to	
human familial hypobetalipoproteinemia.  
These	mice	express	normal	amounts	of	APOB48.	
Homozygotes have greatly reduced levels of 
B6.129P2-Apob tm1Unc/J  002053
plasma	APOB,	beta-lipoproteins,	total	cholesterol,	
plasma triglycerides, fasting chylomicronemia, 
and	HDL	cholesterol.	Homozygotes	also	have	a	
high incidence of exencephaly and hydrocephaly 
(Homanics	et	al.	1993).
Homozygotes for this targeted mutation of 
the	phospholipid	transfer	protein	(Pltp)	gene	are	
viable, fertile, and look and behave normally. 
Their lungs and liver produce no Pltp	mRNA.	
No	plasma	PLTP activity is detected. They have 
marked	decreases	in	plasma	HDL	phospholipids	
(66%),	cholesteryl	esters	(69%),	free	cholesterol	
B6.129P2-Pltp tm1Jia/J  003918
(70%),	and	apoAI.	When	fed	a	high	fat/high	
cholesterol diet, similar reductions are observed, 
as	are	increases	in	VLDL	and	LDL	phospholipid,	
free	cholesterol,	and	cholesteryl	ester	(Jiang	et	al.	
1999,	2001;	Qin	et	al.	2000).
Mice	homozygous	for	this	targeted	mutation	of	
the	phosphatidylcholine	transfer	protein	(Pctp)	
gene are viable, fertile, and look and behave 
normally. PCTP is not detected in the liver cytosol 
of eight day old homozygotes. The lipid content 
and composition of bile and lung surfactant 
secretions	are	normal.	Plasma	cholesterol	
and phospholipid levels are not affected in 
homozygotes fed a normal chow diet, but the 
B6.129-Pctp tm1Bor/J   006607
accumulation	of	small	alpha-migrating	HDL	
particles increases. When mice are fed a high fat, 
high	cholesterol,	cholate-containing	lithogenic	
diet, biliary concentrations of phospholipids, 
cholesterol, and bile salts decrease, but hepatic 
accumulations of phospholipids and cholesterol 
increase.	When	mice	are	fed	a	high	fat	diet,	HDL	
particles	are	normal-sized,	but	plasma	cholesterol	
and phospholipid concentrations are increased.
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Many	homozygotes	for	this	targeted	
mutation	of	the	ATP-binding	cassette,	sub-
family	A	(ABC1),	member	1(Abca1)	gene	die	
perinatally.	Autopsied	pups	exhibit	perivisceral	
hemorrhaging.	Pups	that	survive	beyond	birth	
have no detectable Abca1 gene transcript in 
the liver. Homozygous females have impaired 
placental development and are unable to 
produce	litters.	Plasma	lipids	and	lipoproteins	
are	markedly	reduced;	plasma	cholesterol	is	
decreased	by	approximately	70%;	HDL-C	and	
DBA/1-Abca1tm1Jdm/J  003897
apoAI	are	decreased	by	greater	than	99%;	and	
LDL-C	and	apoB	are	reduced	70%	and	20%	
respectively.	Other	characteristics	observed	are	
an increase in intestinal absorption of dietary 
cholesterol, an impaired ability of macrophages 
to engulf apoptotic cells, and an accumulation of 
lipid-rich	macrophages	and	type	II	pneumocytes	
in the lungs. The pathophysiology of these mice 
is similar to that associated with Tangier disease 
(Calpe-Berdiel	et	al.	2005;	Francone	et	al.	2003;	
McNeish	et	al.	2000).
Homozygotes for this targeted mutation of 
the	caveolin,	caveolae	protein	1	(Cav1)	gene	are	
viable, fertile, and look and behave normally. 
They are intolerant to exercise and slightly 
hyperphagic.	When	four	to	five	months	old,	they	
are	often	smaller	than	their	wild-type	littermates,	
and,	when	a	year	old,	weigh	five	to	seven	grams	
less than those littermates. They are resistant to 
diet-induced	obesity.	They	produce	a	reduced	
amount of white adipose tissue comprised of 
abnormally small adipocytes, but they have 
enlarged and hyperplastic brown adipose tissue. 
Their lipid metabolism and uptake is disrupted, 
resulting in elevated levels of serum triglycerides 
and free fatty acids, and reduced levels of leptin. 
STOCK Cav1tm1Mls/J   004585
Isolated segments from their aortic tissues 
have a diminished vasoconstriction response 
to	the	alpha-1-adrenergic	receptor	agonist,	
phenylephrine, and an enhanced vasorelaxation 
response to acetylcholine. They have thickened 
alveolar septa, hypercellularity, reduced alveolar 
spaces, an increased density of basement 
membranes	and	reticulin	fibers,	and	an	increased	
number	of	endothelial	cells.	MEF	cells	derived	
from these mice are twice as proliferative and 
denser	at	confluence	than	are	those	of	wild-
type littermates. Their endothelial cells lack 
caveolae	(plasmalemmal	vesicles),	and	caveolar	
endocytosis	is	impaired	(Razani	et	al.	2001).	
JAX® Mice Models  Atherosclerosis
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Blood Pressure
Table 4. Mean	diastolic	and	systolic	blood	pressures	
(±SD)	in	25	inbred	mouse	strains	(Tsukahara	et	al.	
2004;	Sugiyama	et	al.	2002).
The Mouse Phenome Project Strains
Blood	pressure	phenotypes	of	numerous	JAX®	Mice	strains	
have	been	characterized	and	published	in	the	Mouse	Phenome	
Database,	www.jax.org/phenome:
•	 Deschepper	and	Gallo-Payet	(2004)	measured	the	
systolic blood pressure and morphologic phenotypes of 
cardiovascular-related	organs	in	13	JAX®	Mice	inbred	strains.
•	 Gavras	et	al.	(2003)	measured	the	effects	of	diet	on	blood	
pressure	and	heart	rate	in	11	JAX®	Mice	inbred	strains.
•	 Svenson	and	Smith	(2005)	measured	the	systolic	blood	
pressure, blood pressure variability across tests, pulse, and 
pulse	variability	across	tests	in	14	JAX®	Mice	inbred	strains.
•	 Kitten	(2003)	performed	a	multi-system	analysis	of	mouse	
physiology	(including	various	blood	pressure	and	other	
cardiovascular	subphenotypes)	in	seven	JAX®	Mice	 
inbred strains.
•	 Sugiyama	and	Tsukahara	et	al.	(2007)	and	Sugiyama	et	al.	
(2002)	determined	the	systolic	and	diastolic	blood	pressure	 
of 25 inbred mouse strains, most of them  
JAX®	Mice	strains	(Table	4).
HLBS Mutants
The	HLBS	Center	has	produced	15	heritable	 
(ready-to-ship)	mutants	and	two	phenotypic	deviants	suitable	 
for	hypertension	research	(Table	3,	page	13).
Strain Diastolic  pressure
Systolic   
pressure
129T2/SvEmsJ 72.5 ± 6.1 115.7 ± 8.7
A/J 66.8 ± 7.6 106.7 ± 5.6
AKR 79.2 ± 6.4 121.2 ± 2.9
ALS/LtJ 76.1 ± 5.1 120.6 ± 6.6
BALB/cAn 72.3 ± 3.6 107.8 ± 3.6
BTBR 62.2 ± 7.6 101.4 ± 2.7
C3H/HeJ 66.8 ± 3.5 100.5 ± 3.2
C57BL/6J 73.2 ± 2.9 114.6 ± 5.3
C57BLKS/J 71.4 ± 5.0 115.4 ± 3.0
CBA/J 71.1 ± 3.2 106.0 ± 7.0
DBA/1J 69.8 ± 3.4 103.4 ± 2.5
DBA/2J 68.4 ± 5.3 107.8 ± 3.5
FGS/Nga 74.4 ± 1.8 111.8 ± 6.3
FVB/N 70.8 ± 4.5 110.0 ± 4.9
KK/Ta 66.8 ± 1.2 111.8 ± 4.1
LP 62.1 ± 11.1 102.7 ± 7.2
MRL 77.1 ± 10.5 113.5 ± 6.5
NOD 85.2 ± 9.1 127.2 ± 4.4
NON 64.4 ± 6.1 104.8 ± 6.2
NZO/HILtJ 86.6 ± 6.9 132.4 ± 3.1
NZW 62.5 ± 8.7 106.9 ± 8.2
PL 70.8 ± 70.6 118.9 ± 7.6
RIIIS 70.3 ± 10.9 115.3 ± 6.7
SJL/J 67.7 ± 2.1 100.6 ± 4.4
SWR/J 86.1 ± 4.7 127.1 ± 3.0
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BPH/2J,	BPL/1J,	and	BPN/3J	are	descended	
from	an	eight-way	cross	from	which	hypertensive	
and hypotensive mouse lines were selected 
(Schlager	and	Sides	1997).
BPH/2J	mice	are	hypertensive.	By	five	weeks	of	
age,	they	have	elevated	systolic	blood	pressures;	
by	150	days	of	age,	their	blood	pressures	are	
60mmHg	higher	than	those	of	BPL/1J	mice.	They	
have higher heart rates, larger hearts and kidneys, 
and	higher	hematocrit	than	do	BPL/1J	mice,	
and lower renin, aldosterone, and angiotensin I 
levels	than	do	BPL/1J	and	BPN/3J	mice.	BPN/3J	
mice are normotensive. They were inbred at the 
same time as and from the same parental strain 
as	BPL/1J	and	BPN/3J,	but	in	the	absence	of	
any selection pressure. They are a normotensive 
control	for	hypertensive	BPH/2J	mice	and	
hypotensive	BPL/1J	mice.
The	original	high	blood	pressure	(HBP)	and	
low	blood	pressure	(LBP)	selected	lines	from	
which the three strains were inbred had several 
biochemical and physiological differences that 
have	not	been	re-examined	in	the	inbred	strains.	
These include differences in brain catecholamines, 
calmodulin concentrations, heat sensitivity, 
BPH/2J   003005
BPL/1J   003006 
BPN/3J   003004
alcohol preference, and longevity. The differences 
in longevity are striking: the hypotensive selected 
lines	live	an	average	of	200-300	days	longer	than	
do the hypertensive selected line. Genetic analysis 
suggested	that	three	to	five	genes	are	responsible	
for the difference in blood pressures between 
BPH/2	and	BPL/1	mice.	A	recent	genome	scan	
of	(BPH/2	x	BPL/1)F2	progeny	revealed	three	
chromosome	locations	co-segregating	with	blood	
pressure.	Two	of	these	sites	were	verified	by	
candidate	gene	co-segregation:	angiotensinogen	
on	Chr	8	and	mouse	kallikrein	binding	protein	
(Serpina3c)	on	Chr	12	(Schlager	and	Sides	1997;	
Uddin	and	Harris-Nelson	2004).
Observations by some of our scientists (Paigen 
and Svenson, pers. comm.) suggest that the 
BPH/2J strain may be a model of preeclampsia. 
It is a subline originating from an eight-way cross 
performed by Schlager and Sides (1997) and 
appears to have some of the same preeclampsia 
phenotypes (including small litters of one or two 
pups) as a different subline from the same cross 
(Dokras et al. 2006; Davisson et al. 2002). We 
are in the process of characterizing BPH/2J to 
determine its potential as an preeclampsia model.
Homozygotes for this targeted mutation of 
the	angiotensin	II	receptor,	type	1a	(Agtr1)	gene	
are viable and fertile. Their blood pressures are 
approximately 24 mmHg lower than those of 
normal	wild-type	siblings	and	do	not	respond	
B6.129P2-Agtr1tm1Unc/J  002682
to angiotensin II infusions. Blood pressures of 
heterozygotes are approximately 12 mmHg lower 
than	those	of	wild-type	siblings	and	respond	
qualitatively to angiotensin II infusions 
(Ito	et	al.	1995).	
Homozygotes for this targeted mutation of the 
nitric	oxide	synthase	3,	endothelial	cell	(Nos3)	gene	
are viable and fertile. Their blood pressure is about 
20	mmHg	higher	than	that	of	wild-type	siblings,	
B6.129P2-Nos3tm1Unc/J  002684
and	they	have	a	decreased	heart	rate.	Females	
weigh	less	than	normal	wild-type	siblings.	They	
are insulin resistant in the liver and peripheral 
tissues	(Shesely	et	al.	1996).
Selected JAX® Mice Blood Pressure Models
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Heart Disorders
Female	heterozygotes	for	the	blotchy	allele	
(Atp7aMo-blo),	a	targeted	mutation	of	the	ATPase,	
Cu++	transporting,	alpha	polypeptide	(Atp7a)	
gene, are viable and fertile. They have irregular 
patches	of	light-colored	fur.	Hemizygous	males	
and homozygous females have reduced viability, 
and many are infertile. Hemizygotes and 
homozygotes are light all over with no blotching, 
Homozygotes for this targeted mutation of the 
nitric	oxide	synthase	3,	endothelial	cell	(Nos3)	
gene are viable and fertile. They have a low  
Homozygotes for this targeted mutation of 
the	clusterin	(Clu)	gene	are	viable,	fertile,	and	
look	and	behave	normally.	Clusterin	is	a	widely	
expressed circulating glycoprotein of unknown 
function	associated	with	Alzheimer’s	disease,	
cerebral palsy, stroke, apoptosis, autoimmune 
myocarditis	and	other	inflammatory	injuries,	
kidney	disease,	and	skin	carcinogenesis	(Imhof	 
et	al.	2006;	McLaughlin	et	al.	2000).	It	plays	a	
B6Ei.Cg-Atp7aMo-blo/J  002044
B6.129P2-Nos3tm1Unc/J  002684
B6.Cg-Clutm1Jakh/J   005642
are usually small, and occasionally have deformed 
hind	legs.	Most	hemizygotes	and	homozygotes	
have defective aortic elastin and die of an aortic 
aneurysm. Hemizygous males have enlarged air 
spaces	in	their	lungs	(emphysema),	probably	
because they have defective elastin and collagen 
(Andrews	et	al.	1975;	Brophy	et	al.	1988).
heart	rate.	Females	weigh	less	than	normal	
wild-type	siblings	(Feng	et	al.	2002;	Li	et	al.	2004;	
Ojaimi	et	al.	2005).
central role in the remodeling of ischemic damage 
(Imhof	et	al.	2006).	Clu-deficient	mice,	
particularly	females,	develop	more	severe	myosin-
induced	myocarditis	than	do	wild-type	mice,	
suggesting that clusterin limits the progression of 
autoimmune myocarditis and protects the heart 
from postinflammatory tissue destruction  
(McLaughlin	et	al.	2000).
Homozygotes for this targeted mutation of 
the	gap	junction	membrane	channel	protein	
alpha	1	(Gja1)	gene	die	at	birth.	The	cause	of	
death is a failure in pulmonary gas exchange 
caused by a swelling and blockage of the right 
ventricular outflow tract from the heart. The 
cardiac abnormality involves a delayed looping 
of the ascending limb of the heart tube, which 
includes the right ventricle and the outflow tract. 
B6;129S-Gja1tm1Kdr/J  002201
This predisposes homozygotes to malformations 
of the subpulmonary outflow tract and tricuspid 
valve. The mutation also predisposes homozygotes 
to lens cataracts and causes a severe reduction 
of germ cell numbers. Both neonatal and adult 
heterozygotes have slow ventricular epicardial 
heartbeats	(Reaume	et	al.	1995).
HLBS Mutants
The	HLBS	Center	has	produced	13	mutant	models	(eight	
heritable,	and	ready-to-ship)	for	researching	heart	disorders	
(see	Table	3,	page	13).
Selected JAX® Mice Models
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Metabolic Syndrome (Syndrome X)
Until recently, few animal models were known 
to display the constellation of obesity, type 2 
diabetes, hypertension, atherosclerosis, and 
other abnormalities collectively called metabolic 
syndrome	or	syndrome	X.	Males	of	this	Ldlr-
deficient	JAX®	Mice	strain	may	be	such	a	model.	
Ldlrtm1Her homozygotes have long been used as 
a model for cardiovascular disease, and recent 
studies indicate that they may be excellent models 
of	diet-induced	metabolic	syndrome.	Males	fed	a	
The	B6.129-Ppargtm2Rev/J strain, developed in 
the	laboratory	of	Dr.	Ronald	Evans	at	The	Salk	
Institute	by	Dr.	Yaacov	Barak,	currently	at	The	
Jackson Laboratory, possesses loxP sites flanking 
exons 1 and 2 of the peroxisome proliferator 
activated	receptor	gamma	(Pparg)	gene,	which	
is abundantly expressed in adipocytes. In 
conjunction	with	a	Cre	recombinase-expressing	
strain,	this	strain	can	be	used	to	generate	tissue-
specific	Pparg	mutants.	For	example,	when	this	
B6.129S7-Ldlrtm1Her/J   002207
B6.129-Ppargtm2Rev/J  004584
diabetogenic diet develop hypertriglyceridemia, 
high serum cholesterol levels, hyperleptinemia, 
slightly higher insulin and moderately higher 
plasma	glucose	levels	than	do	C57BL/6	mice	
fed a diabetogenic diet, obesity, high vascular 
calcification,	atherosclerotic	plaques	comparable	
to those that form in mice of the same strain fed 
a chow diet, and elevated free fatty acid levels 
(Merat	et	al.	1999;	Towler	et	al.	1998,	Schreyer	 
et	al.	2002).
strain	is	mated	to	B6.Cg-Tg(Fabp4-cre)1Rev/J	
(005069),	offspring	are	produced	in	which	Pparg 
is deleted. These offspring develop progressive 
lipodystrophy	and	late	onset	syndrome	X-like	
symptoms, including modestly elevated plasma 
free fatty acid and triglyceride levels, decreased 
plasma	leptin	and	ACRP30	levels,	increased	
hepatic glucogenesis, and increased insulin 
resistance	(He	et	al.	2003;	Hevener	et	al.	2003).
JAX® Mice Models Metabolic Syndrome
22          The Jackson Laboratory 
JAX® In Vivo Services
JAX®	Services	is	a	comprehensive	and	integrated	set	of	
mouse breeding and research services designed to provide 
you	with	efficient	and	cost-effective	solutions	to	your	mouse-
based	research.	The	services	are	based	on	nearly	80	years	of	
experience in mouse husbandry and genetic research and are 
conducted in accordance with the highest standards of animal 
health and genetic quality.
Several	services	that	may	be	appropriate	for	cardiovascular	
research	are	described	below.	For	more	information	on	
these	and	other	services,	please	contact	your	Regional	
Representative	(contact	information	can	be	found	on	the	
following	website:	www.jax.org/jaxmice/services/manager),	
visit	the	JAX®	Services	website,	www.jax.org/jaxmice/
services/invivo,	or	contact	JAX®	Services	at	 
jaxservices@jax.org,	1-800-422-6423,	or	1-207-288-5845.	
We provide fully customizable target validation and 
efficacy testing services with access to the world’s largest 
collection	of	specialized	mouse	models.	Our	Study	Directors	
and research scientists bring their expertise and collective 
knowledge of mouse physiology and genetics research to 
work for you.
Our	state-of-the-art	phenotyping	laboratory	provides	a	
broad	array	of	high-throughput,	cost-effective,	and 
non-invasive	test	platforms	for	model	characterization,	
evaluation of key physiological parameters, drug target 
validation,	and	drug	efficacy	testing	(Table	5).	Our	in-house	
services are complemented by a network of providers to offer 
comprehensive disease endpoint measurements.
We have expertise with a variety of therapeutic areas, 
including atherosclerosis, osteoporosis, subcutaneous 
and orthotopic xenograft models of cancer, inflammatory 
bowel disease, blood disorders, neuromuscular disease, 
regenerative medicine, autoimmune disorders, pain models, 
asthma, dermatology, and metabolic disorders, including 
diabetes	and	obesity.	Our	dedicated,	experienced	staff	help	
select the most clinically relevant model for your protocol. 
We have performed in vivo	studies	in	over	100	mouse	
models to date.
JAX®	In Vivo	Services	are	highly	customizable.	We	manage	
entire	projects	and	work	closely	with	you	to	ensure	that	
custom protocols are properly executed
Compound Dosing
IP,	IV,	SC,	PO,	ID
High	pressure	tail	vein	injections
Inhalation
In the food or water
Intramuscular, intrarectal
IV catheters
Osmotic	minipumps	(SC	or	IP)
SC	drug	pellets
Experimental Methods
Biospecimen collection
Digital	caliper	measurements
In vitro cell preparation: cell isolation, culture,  
characterization
Mouse	model	induction
Necropsies,	tissue	harvests
Surgical	techniques
SC	xenograft	and	orthotopic	transplantation
Stem	cell	engraftment
Physiological and Behavioral Tests*
Activity	Monitoring,	including	locomoter,	rearing
Body	tissue	composition	by	DEXA	and	MRI
C02	production/O2	uptake,	food	&	water	intake
Glucose tolerance, insulin tolerance, glucose measurement
Heart	rate,	ECG
Locomotor	anxiety	test	analyzed	by	SMART	software
Morris	water	maze,	Radial	arm	maze
Respiratory	function	by	Whole	Body	Plethysmograph
Rotorod,	grip	strength,	gait	analysis
Systolic	and	diastolic	blood	pressure,	pulse
Thermal pain reflex
Supporting Services
Bioanalytical
Blood and urine glucose
CBC
Clinical	chemistry
Histological	services	and	IHC
Immunophenotyping
Lipid distribution
Metabolic	assays
Multiplex	analysis	of	serum	hormones	and	cytokines
Access	to	specialized	imaging:	biophotonic,	MRI,	 
micro-CT,	PET
Table 5. Summary	of	JAX®	In Vivo	Services.
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VCD-induced Menopause
Figure 1. Cyclicity,	estrogen	levels,	and	FSH	levels	
are	similar	in	VCD-induced	mouse	and	human	
menopause.	The	OVX	mouse	goes	into	menopause	
quickly	and	skips	peri-menopause,	(the	one	to	10	
years	in	humans	before	menstrual	cycles	cease).	Post-
menopause	refers	to	the	year	after	peri-menopause.	
Values	for	VCD-induced	menopause	are	relative	to	
the	beginning	of	the	15-day	VCD	injection	protocol.
We can produce mouse models that mimic the 
physiological changes occurring in human perimenopause, 
enabling researchers to better understand the associations 
between both menopause and hormone replacement therapy 
and susceptibility to heart disease.
The only rodent models previously available for modeling 
menopause	were	ovariectomized	(OVX)	rats	and	mice.	
However,	almost	90%	of	menopausal	women	still	have	
their	ovaries.	Our	service	uses	the	industrial	chemical	
4-vinylcyclohexene	diepoxide	(VCD)	to	selectively	accelerate	
the natural loss of small primordial and primary follicles 
without affecting the ovary or other tissues, resulting in an 
endocrine state that more closely mimics human menopause 
(Fig.	1)	(Mayer	et	al.	2002).
VCD-induced	menopause	is	a	particularly	powerful	tool	
because it works with most mouse strains, including models 
of	atherosclerosis.	For	example,	Mayer	et	al.	2004,	2005)	
found	that	when	VCD-induced	menopausal	low-density	
lipoprotein-(Ldlr-)	deficient	mice	(B6.129S7-Ldlrtm1Her/J, 
002207),	which	are	susceptible	to	atherosclerosis,	receive	
17β-estradiol	supplements,	they	develop	significantly	fewer	
atherosclerotic	plaques	than	do	either	non-supplemented	
controls	or	non-supplemented	OVX	mice.	
VCD-induced	menopause	may	be	particularly	
appropriate for cardiovascular research when used with 
the	following	four	JAX®	Mice	strains:	C57BL/6J	(000664),	
an	atherosclerosis-susceptible	strain;	C3H/HeJ	(000659),	
an	atherosclerosis-resistant	strain;	B6.129S7-Ldlrtm1Her/J 
(002207),	a	strain	with	normally	high	serum	cholesterol	
levels and extremely high levels when fed an atherogenic 
diet;	and	B6.129P2-Apoetm1Unc/J	(002052),	another	strain	
with	high	serum	cholesterol	levels.	A	study	by	our	Animal	
Husbandry	and	Performance	Group	demonstrated	the	
efficacy	of	VCD-induced	menopause	in	these	strains.	VCD	
treatments significantly decreased the number of primordial 
and primary follicles, resulting in a significant increase in 
FSH	levels	(JAX®	NOTES	2007).	For	additional	cost,	this	
service can be adapted to other strains.
JAX® Services VCD-induced Menopause
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JAX® Surgical & Tissue Collection Services
Table 8. Selected	surgical	procedures	and	biological	samples	available	from	JAX®	Services.
Foamy	macrophages	in	the	subendothelial	space	of	a	 
mouse aorta.
Surgical Procedures Tissue and Fluid Samples
•	 Adrenalectomy
•	 Adrenal	demedullation
•	 Brown	adipose	fat	denervation
•	 Castration	-	Orchiectomy
•	 Catheter	(jugular,	femoral,	carotid)
•	 Subcutaneous	hormone	pellet	implant
•	 Hysterectomy
•	 Intracerebroventricular	cannulation
•	 Intrathymic	injections
•	 Kidney	capsule	implant
•	 Nephrectomy	(5/6	and	unilateral)
•	 Olfactory	bulbectomy
•	 Osmotic	pump	implants
•	 Ovarian	transplant
•	 Ovario-hysterectomy
•	 Ovariectomy
•	 Skin	graft	(body	or	tail)
•	 Sialectomy
•	 Splenectomy
•	 Subq	implant
•	 Telemetry	Implant	(PA-C10	BP	monitor)
•	 Thymectomy
•	 Thyroid-parathyroidectomy
•	 Vasectomy
•	 Vagotomy
•	 Bile
•	 Blood,	Serum,	Plasma	(pooled,	non-pooled)
•	 Adrenal	glands
•	 Aorta
•	 Bone	(vertebrae	and	femur)
•	 Bone	marrow
•	 Brain	and	Spinal	cord
•	 Diaphragm
•	 Embryonic	tissue
•	 Eyes,	Retina
•	 Fat	(brown	and	white	depots)
•	 Head
•	 Heart,	Liver,	Kidneys,	Lungs
•	 Leg
•	 Mammary	glands
•	 Ovaries,	Testicles,	Uterus,	Prostate
•	 Pineal	gland,	Pituitary	gland
•	 Polyps
•	 Salivary	gland	-	Submandibular
•	 Skeletal	muscle
•	 Skin	(with	or	without	hair)
•	 Spleen,	Thymus
•	 Stomach,	Small	intestine,	Colon,	Pancreas
Our	expert	surgeons	can	perform	over	60	types	of	
standard	and	custom	surgical	procedures.	Conventional	
techniques can be modified, or new ones can be developed 
to meet even the most demanding research requirements. 
All	surgeries	are	performed	at	an	appropriate	health	status	
in surgical suites of a barrier facility. We can also collect and 
provide you with tissues or fluid samples. Table 8 below lists 
most	of	our	surgical	procedures	and	biospecimens.	For	a	
complete list and prices, please visit our website,  
www.jax.org/jaxmice/services/surgical_pricing.
JAX® Services Surgical and Tissue Collection
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Offered	in	Maine,	and	California,	our	Breeding	and	
Colony	Management	Services	are	designed	to	save	you	
time, space, money, and to simplify all aspects of managing 
your mouse colonies.
JAX®	Breeding	and	Colony	Management	services	support	
your research with the following:
•	 Nearly 80 years of experience in mouse genetics and 
colony management
•	 State-of-the-art technologies in reproductive science 
and genetic analysis
•	 World-class expertise with an array of in vitro 
fertilization	(IVF)	techniques
•	 Experience in optimizing animal housing space  
to	deliver	standard	and	customized	breeding	projects	 
on schedule, on budget, and according to  
your specifications
•	 Capability to rapidly expand breeding colonies by 
drawing from large quantities of breeding stock
•	 Breeding strategies customized to your needs, whether 
for large or small quantities of mice, from pedigreed 
stock to preserve genetic integrity
JAX® Breeding Service
This service helps you quickly and efficiently achieve your 
objectives,	whether	to	relieve	capacity	constraints	at	your	
facility, rederive mice to improve the health of your colonies, 
or	manage	complex,	multiple-gene	crossbreeding	projects.	
Using	investigator-supplied	or	JAX®	Mice	strains,	this	service	
maintains	and	ships	mice	to	you	as	needed.	Our	California	
facility	can	also	handle	projects	which	require	housing	mice	
in flexible film isolators.
Breeding and Colony Management Services
 
JAX® Dedicated Supply Service
Many	of	our	strains	are	available	only	from	our	
cryopreserved repository or from small colonies in limited 
quantities.	Our	Dedicated	Supply	Service	can	custom	build	
a colony of these strains, so you receive the mice you need 
when	you	need	them.	Our	Dedicated	Supply	personnel	
know all the tricks of the trade for maintaining difficult 
strains	and	for	expanding	colonies	of	low-demand	strains	
efficiently	and	cost-effectively.	
JAX® Speed Expansion Service
Expanding colonies to meet increased demand or to 
produce	a	burst	of	same-age	mice	can	be	expensive	and	time	
consuming.	Using	IVF	techniques,	we	can	do	this	rapidly	
and	cost-effectively.	This	service	is	particularly	useful	for	
quickly producing large quantities of specific pathogen free 
(SPF),	same-age	mice.
JAX® Services Breeding and Colony Management
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Cryopreservation and Recovery Services
JAX® Sperm Cryopreservation &  
Recovery Service
Our	scientists	have	developed	the	first	truly	reliable	and	
cost-effective	sperm	cryopreservation	and	recovery	service	
for	knock-out	and	transgenic	strains	with	common	genetic	
backgrounds. We recover cryopreserved sperm and use 
them	to	quickly	produce	a	large	colony	of	single-age	SPF	
mice.	This	service	includes	a	quality	control	check	(IVF	
rate	for	the	frozen	sperm)	and	three	years	of	liquid	nitrogen	
storage	(additional	years	of	storage	can	be	purchased).
JAX® Custom (Embryo)  
Cryopreservation Service
We can cryopreserve embryos of homozygous and hemi/
heterozygous inbred, mutant, and genetically modified 
lines	of	mice.	Cost	varies	depending	on	strain	background,	
fertility, and the number of mice provided. This service 
includes	five	years	of	liquid	nitrogen	storage	(additional	
years	of	storage	can	be	purchased). 
Combined JAX® Speed Rederivation and  
JAX® Sperm Cryopreservation Service
In	this	combined	service,	our	JAX®	Speed	Rederivation	
Service	uses	IVF	to	quickly	rederive	your	mouse	strain	
to	SPF	status,	and,	at	no	extra	cost,	our	JAX®	Sperm	
Cryopreservation	&	Recovery	service	cryopreserves	
sperm from the strain for three years, protecting it from 
accidental loss or contamination and freeing up valuable 
mouse room space. This combined service is applicable for 
strains	with	transgenes,	targeted	mutations,	or	chemically-
induced mutations on the most commonly used genetic 
backgrounds:	C57BL/6J,	FVB/NJ,	NOD/ShiLtJ,	BALB/cByJ,	
BALB/cJ,	DBA/1J,	DBA/2J,	C3H/HeJ,	hybrid	combinations	
of	these	strains,	and	B6;129	hybrids.
Our	new	JAX®	Sperm	Cryopreservation	and	Recovery	
Service	produces	much	higher	embryo	fertilization	rates	
from cryopreserved sperm than traditional methods.
JAX® Services Cryopreservation and Recovery
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JAX® Genetic Analysis and Research Services
Our	scientists	have	developed	a	panel	of	2,199	informative	
and	easily-assayed	single	nucleotide	polymorphic	(SNP)	
markers. These markers are an average of approximately 
1.5	Mb	or	0.75cM	apart	and	often	represent	the	informative	
allele	in	at	least	two	strains	(Petkov	et	al.	2004a,	2004b).	We	
use	this	SNP	panel	for	many	of	our	services,	including	those	
described below.
Using	our	SNP	panel,	we	can	characterize	the	genetic	
make-up	of	virtually	any	mouse	strain.	As	examples,	we	can	
detect	inter-strain	genetic	contamination,	determine	the	
degree of congenicity in congenic strains, and detect cryptic 
unlinked	segments	of	residual	donor	DNA	in	congenic	strains.
JAX® Speed Congenic Development Service
This	service	uses	a	marker-assisted	breeding	strategy	to	
produce congenic strains in only 15 to 18 months, reducing 
the number of mice needed, as well as facility, equipment, 
and personnel costs.
JAX® Genome Scanning Service
We designed this service for those of you who prefer to 
construct your own congenic or consomic strains but wish to 
take	advantage	of	our	SNP-marker	panel	to	type	and	select	
the offspring for each backcross. The process is easy: simply 
send	us	tail	samples	from	backcross	offspring	(minimum	
of	six	to	10	recommended	per	generation),	and	we	type	the	
tails and tell you which mice to use for the next backcross
JAX® Gene Expression Service
Accelerate	your	research	by	using	JAX®'s	well	established	
Gene	Expression	Service.	The	service	includes	nucleic	
acid preparation, chip/array hybridization, and detailed 
statistical analysis, using unique statistical tools developed 
at The Jackson Laboratory. We have successfully analyzed 
thousands of mouse tissues for our own scientists, and  
are now pleased to offer this service to the broader  
scientific community.
JAX® Gene Mapping Service
Using	our	SNP-marker	panel,	we	can	analyze	mouse	
tissue	or	processed	DNA	samples	from	F2	or	N2	progeny	
and localize a gene of interest. We can also help you select 
the	most	appropriate	strains	to	produce	the	F2	or	N2	
progeny. You receive results approximately six weeks after we 
complete the crosses and collect tissue samples. This service 
is	appropriate	for	mice	with	single-gene	mutations.
JAX® SNP-Assisted QTL Mapping Service
QTL	mapping	has	become	a	very	important	tool	for	
finding the alleles that contribute to complex human 
diseases, such as atherosclerosis and hypertension. These 
diseases are continuous and modulated by a group of alleles 
interacting with each other and the environment. Using our 
SNP	marker	panel,	we	can	locate	and	estimate	the	effect	of	
contributing alleles.
JAX® Services Genetic Analysis and Research Services
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JAX® Mice Database
You	can	find	more	information	on	over	250	JAX®	Mice	
models	suitable	for	cardiovascular	research	(including	 
those	described	herein)	in	the	JAX®	Mice	Database.	Using	
the	Quick	Query	Form	(www.jax.org/jaxmice/query),	
you may search the database using gene or allele symbols, 
common names, stock numbers, keywords, phenotype terms 
from	the	Mouse	Phenotype	Ontology	vocabulary	in	the	
Mouse	Genome	Database,	human	disease	terms	from	the	
Online	Mendelian	Inheritance	in	Man	(OMIM)	vocabulary,	
or research areas.
Select	the	strain	name	to	view	the	Strain	Data	Sheet.	
Each	Strain	Data	Sheet	includes	nomenclature	information,	
genetic and phenotypic characteristics, strain development 
information, research applications, references, and 
availability and pricing information.
Mouse Phenome Database
The	Mouse	Phenome	Database	(MPD,	www.jax.org/
phenome)	is	the	database	for	the	Mouse	Phenome	Project,	
a coordinated international effort to establish a collection 
of baseline phenotypic data for a set of commonly used 
and genetically diverse inbred mouse strains. Housed at 
The	Jackson	Laboratory,	The	MPD	includes	baseline	and	
diet-induced	phenotypic	data	for	many	cardiovascular	
phenotypes, including cholesterol and triglyceride levels, 
blood pressure, and susceptibility to atherosclerosis. 
The database characterizes these and other phenotypes 
by strain and sex. Investigators may download protocols 
and raw data, review related data published in the scientific 
literature, use query tools to analyze data, review current 
project	information,	participate	in	the	Mouse	Phenome	
Project,	and	subscribe	to	“PHENOME-LIST,”	a	forum	for	
discussing	Phenome	Project-related	items.	The	Mouse	
Phenome	Database	is	fully	integrated	with	the	Mouse	
Genome	Database	(www.informatics.jax.org).
Online Resources
Online Resources for Mouse-based Cardiovascular Research
JAX® HLBS Center
The	Jackson	Laboratory’s	Center	for	New	Mouse	Models	
of	Heart,	Lung,	Blood,	and	Sleep	Disorders	(HLBS)	is	one	of	
five	Programs	for	Genomic	Applications	(PGAs)	established	
in	September,	2000,	by	the	National	Heart,	Lung,	and	Blood	
Institute to advance functional genomic research related to 
heart,	lung,	blood,	and	sleep	(www.nhlbi.nih.gov/resources/
pga).	The	goal	of	The	Jackson	Laboratory	PGA	is	to	provide	
the biomedical research community with new information, 
tools, and resources for understanding the genetic bases 
of atherosclerosis, hypertension, lung function, blood 
formation, thrombosis, obesity, and sleep function.
Among	the	new	tools	produced	by	the	Center	are	
chemically-induced	mutant	mice,	many	of	them	suitable	
for cardiovascular research. To produce these mutants, the 
Center	uses	N-ethyl-N-nitrosourea	(ENU)	and	B6	mice	
as	the	mutagen	and	strain	of	choice	respectively.	Once	
new mutants are characterized and proven heritable, they 
are made available to academic researchers for the cost 
of	shipping	only	(for-profit	organizations	are	charged	an	
additional	$250.00	USD).	Instructions	for	ordering	are	on	
the	Center’s	website.	
To	date,	the	Center	has	identified	over	400	phenotypic	
deviants,	about	100	of	which	have	been	proven	heritable.	
As	a	participant	in	the	Mouse	Phenome	Project,	the	
Center	is	in	the	process	of	comprehensively	characterizing	
the	heart,	lung,	blood,	and	sleep	phenotypes	of	the	Mouse	
Phenome	Project	strains.	This	is	allowing	scientists	to	
choose the strains most appropriate to cross for identifying 
QTLs	associated	with	cardiovascular,	respiratory,	and	related	
phenotypes.	HLBS	and	Mouse	Phenome	Project	participants	
have already characterized coagulation, heart rate, blood 
pressure, electrocardiogram, plasma lipid, cardiovascular 
organ	weight,	atherosclerosis	susceptibility	(pathogen-
accelerated	and	pathogen-free),	lung	volume,	respiratory	
rate, airway hyperreactivity, and related phenotypes for some 
or	all	Phenome	strains.	Data	are	published	and	publicly	
accessible	in	the	Mouse	Phenome	Database.	Additionally,	
the	Center	has	used	its	strain	survey	data	to	carry	out	QTL	
crosses	for	baseline	peripheral	blood	counts,	HDL	levels,	and	
disordered sleep.
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Online Resources
Cardiogenomics PGA and Website
The	goal	of	the	Cardiogenomics	Program	for	Genomics	
Application	(PGA)	is	to	characterize	the	genetic	and	
environmental factors that regulate cardiovascular function 
and	disease.	The	PGA	also	provides	extensive	training	in	
cardiovascular	research:	ongoing	journal	clubs	and	seminars,	
symposia	at	major	conferences,	and	workshops	relevant	to	
cardiovascular research. 
The	Cardiogenomics	website	 
(cardiogenomics.med.harvard.edu/home)	publishes	 
high quality and comprehensive data for the genomics of 
structural and functional adaptation of the cardiovascular 
system. It integrates expression data from animal models 
and human tissue samples, mutation screening of candidate 
genes	in	patients,	and	DNA	polymorphisms	in	awell-
characterized general population. This data set will serve as a 
benchmark for future basic, clinical, and pharmacogenomic 
studies. 
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We host several courses that are particularly helpful 
to	cardiovascular	researchers.	Most	of	them	are	offered	
yearly, are one to two weeks long, and consist of a mixture 
of	lectures,	hands-on	workshops,	discussion	groups,	and	
tutorials.	Many	are	held	in	a	retreat-like	setting	at	the	High	
Seas	facility	overlooking	the	ocean	in	Bar	Harbor.	 
To ensure a supportive learning atmosphere with exceptional 
interaction between students and faculty, the courses are 
generally	limited	to	35	participants.	We	recommend	that	
you	register	early.	For	more	details	on	content,	registration,	
enrollment limits, and continuing education credits for 
Jackson	Laboratory	courses,	see	the	Courses	and	Conference	
website	at	www.jax.org/courses.
Comprehensive Approaches to the In Vivo 
Assessment of Cardiovascular Function  
in Mice
This workshop focuses on assessing cardiovascular 
function in mouse models. Lectures are given by leaders in 
the field of cardiovascular physiology, pharmacology, and 
pathology.	Participants	are	taught	to	use	the	Visualsonics	
Vevo	770	system	to	perform	non-invasive	high-resolution	
ultrasound,	use	telemetry	(DataSciences	International)	and	
catheter-dependent	(ADInstruments)	approaches	to	monitor	
cardiovascular parameters in vivo, analyze data collected 
during the workshop, perform various surgeries, and 
administer anesthetics.
Genomic and Proteomic Approaches to 
Complex Heart, Lung, Blood, and  
Sleep Disorders
Participants	in	this	highly	acclaimed,	intensive,	nine-day	
course learn how to use statistics, molecular biology and 
genetics to analyze complex diseases such as atherosclerosis, 
hypertension, and asthma in humans and animal models. 
They learn to detect the genetic basis of disease, perform 
linkage analysis, conduct genome scans, analyze quantitative 
trait loci, detect gene interactions, map complex disease 
genes, clone genes, and characterize gene functions. They are 
introduced to contemporary approaches of gene discovery, 
such as mutagenesis and microarray analysis, are introduced 
to	the	latest	bioinformatics	tools	(such	as	OMIM,	MGD,	
Unigene,	GeneBank,	Blast,	Gene-scan,	SwissProt,	and	
Entrez),	and	they	engage	in	in-depth	discussions	about	the	
social and ethical aspects of generating and using  
genetic information.
Courses and Conferences
Phenotyping Mouse Models of Human  
Lung Disease
This	five-day	workshop	provides	hands-on	training	in	
phenotyping mouse mutants for cardiovascular defects, and 
heart, lung, blood, and sleep disorders. The course focuses 
primarily	on	measuring	blood	pressure,	ultrasound,	EKG	
and coagulation profiles, and the theory and methods used 
for screening sleep and respiratory mutants.
Annual Short Course on Medical and 
Experimental Mammalian Genetics
Offered	here	every	summer	for	nearly	50	years,	this	
two-week	course	features	daily	morning	and	evening	
lectures	and	afternoon	mini-symposia,	workshops,	tutorials,	
and demonstrations. The course implicitly focuses on 
translational biology and clinical applications of biomedical 
research. It covers three broad areas:  
1)	genetics	in	experimental	animals	and	humans,	2)	the	
relationship of heredity to disease in experimental animals 
and	humans,	and	3)	the	importance	of	molecular	genetics	
in	diagnosing	and	treating	inherited	disorders.	Many	of	the	
lectures, workshops, and symposia are either on or include 
cardiovascular research. 
Annual Workshop on the Pathology of Mouse 
Models for Human Disease
This	week-long	workshop	provides	intensive	training	
sessions in pathology and histopathology and includes 
didactic sessions on particular diseases and models. 
Participants	interact	with	prominent	mouse	pathologists	 
and geneticists from leading research institutions.
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Courses and Conferences
Short Course on Systems Genetics
This	seven-day	course	focuses	on	using	the	mouse	as	
a paradigm for mathematical approaches to studying 
complex	human	diseases.	The	course	objectives	are	to:	
1)	help	geneticists	and	statisticians	better	understand	
and incorporate each others’ skills in analyzing complex 
phenotypes	(most	notably,	disease);	2)	help	researchers	 
more critically evaluate the evidence of genetic and 
biomolecular	studies;	3)	help	investigators	use	contemporary	
statistics	to	design	molecular	and	genetic	studies;	and	
4)	develop	professional	relationships	that	promote	
interdisciplinary research.
Methods in Human Embryonic  
Stem Cell Research
This	five-day	workshop	teaches	participants	state-of-
the-art	techniques	on	how	to	culture,	manipulate,	and	
differentiate	embryonic	stem	(ES)	cells	from	humans	and	
other species in vitro. 
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Having access to our outstanding staff of research 
scientists, the members of our highly skilled, informed,  
and	dedicated	Technical	Information	Support	team	are	well	
equipped to answer your technical questions, help  
you select mouse models, and give you information to 
facilitate your research. You can call them at  
1-800-422-6423,	1-207-288-5845,	send	an	email	to	
micetech@jax.org,	or	fill	out	and	send	the	email	contact	
form	at	www.jax.org/jaxmice/micetech.
JAX® Mice News
Subscribe to JAX® Mice News, our email publication, and be the first to learn about new 
cardiovascular research models. JAX® Mice News is also a great way to keep informed about the 
latest JAX® Mice and Services, online bioinformatics resources, courses and conferences, and 
research news from The Jackson Laboratory. To begin receiving this valuable resource, complete 
the online subscription form at www.jax.org/jaxmice/news/quick.
Support Services
Technical Support
Members	of	our	personal,	courteous,	and	efficient	
Customer	Service	staff	understand	what	it’s	like	to	be	a	
customer and are particularly attuned to the needs of 
research scientists. They will do everything possible to 
ensure	that	you	receive	the	JAX®	Mice	you	need,	in	the	
quantities you need, and on time. To better serve our 
We	serve	the	global	biomedical	research	community.	Our	
talented,	knowledgeable,	and	friendly	team	of	Regional	
Representatives	will	gladly	speak	with	you	about	how	our	
resources	and	JAX®	Mice	and	Services	can	facilitate	your	
research and make the best use of your research dollars.  
Customer Service
Regional Representatives
customers,	our	Customer	Support	Representatives	accept	
orders	for	JAX®	Mice	until	3:00	PM	Pacific	time	(6:00	PM	
ET).	Available	mice	ordered	by	that	time	are	packed	and	
shipped	the	next	day.	To	order	mice	(if	to	U.S.	destinations),	
call	1-800-422-6423,	1-207-288-5845,	or	send	an	email	
to	orderquest@jax.org.	To	order	mice	from	international	
destinations,	call	1-207-288-5845.
Contact	information	for	your	local	Regional	Representative	
can	be	found	on	the	following	website:	www.jax.org/jaxmice/
services/manager.	For	a	list	of	international	distributors,	see 
www.jaxmice.jax.org/orders/international/distributors.
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